Benedict Financial Advisors Inc. Makes New Investment in Stryker Corporation $SYK

Benedict Financial Advisors Inc. acquired a new stake in Stryker Corporation (NYSE:SYK) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor acquired 5,732 shares of the medical technology company’s stock, valued at approximately $2,119,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Brighton Jones LLC raised its position in Stryker by 15.4% in the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after purchasing an additional 609 shares during the last quarter. Janney Montgomery Scott LLC grew its position in shares of Stryker by 23.6% during the 2nd quarter. Janney Montgomery Scott LLC now owns 85,479 shares of the medical technology company’s stock worth $33,818,000 after buying an additional 16,322 shares during the period. Capital Investment Advisors LLC raised its position in shares of Stryker by 1.8% during the 2nd quarter. Capital Investment Advisors LLC now owns 3,299 shares of the medical technology company’s stock valued at $1,305,000 after acquiring an additional 59 shares during the last quarter. Truist Financial Corp increased its holdings in Stryker by 3.5% in the second quarter. Truist Financial Corp now owns 107,995 shares of the medical technology company’s stock valued at $42,726,000 after purchasing an additional 3,656 shares during the last quarter. Finally, Cooper Financial Group increased its stake in shares of Stryker by 90.3% in the 2nd quarter. Cooper Financial Group now owns 2,205 shares of the medical technology company’s stock valued at $872,000 after acquiring an additional 1,046 shares during the last quarter. 77.09% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

SYK has been the topic of several research analyst reports. BTIG Research reaffirmed a “buy” rating and set a $410.00 price objective on shares of Stryker in a research note on Friday, November 14th. UBS Group set a $408.00 target price on shares of Stryker in a report on Monday, October 13th. Barclays boosted their price target on Stryker from $443.00 to $453.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 22nd. Piper Sandler reissued an “overweight” rating on shares of Stryker in a research report on Tuesday. Finally, Raymond James Financial upgraded Stryker from a “market perform” rating to an “outperform” rating and set a $418.00 price target for the company in a research note on Tuesday, January 6th. Twelve equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, Stryker has an average rating of “Moderate Buy” and a consensus price target of $425.94.

Key Stryker News

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Quarterly beat: Stryker reported adjusted Q4 EPS $4.47 and revenue $7.17B, topping consensus on both measures — a clear near‑term positive for revenue and profitability trends. Stryker (SYK) Surpasses Q4 Earnings and Revenue Estimates
• Positive Sentiment: Raised profit outlook: Management raised its full‑year profit forecast, citing strong implant and capital product demand — a catalyst for forward earnings expectations. Stryker raises annual profit forecast on strong sales for medical devices
• Positive Sentiment: Solid full‑year momentum and guidance: FY2025 adjusted EPS and margins expanded (adjusted EPS $13.63; adjusted operating margin +100 bps year) and management guided 2026 organic net‑sales growth ~8.0%–9.5% with adjusted EPS $14.90–$15.10 — supports medium‑term upside. Stryker reports 2025 operating results and 2026 outlook
• Neutral Sentiment: Analyst/street context: Several firms maintain positive ratings (e.g., Piper Sandler reaffirmed a Buy), and sell‑side median targets remain well above the current price — supports sentiment but may already be priced in. Piper Sandler Remains a Buy on Stryker (SYK)
• Neutral Sentiment: Conference call / details ahead: Management held an earnings call and provided granular segment math and non‑GAAP reconciliations — useful for modeling but unlikely to shift the stock absent new guidance tweaks. Press release & conference details
• Negative Sentiment: Mixed segment dynamics: MedSurg & Neuro showed double‑digit growth, but spinal implants and some orthopaedics subcategories remain weak or volatile — a potential drag on sustained top‑line upside. Stryker Reports Strong Q4 and Full-Year 2025 Results
• Negative Sentiment: One‑offs and legacy charges: Prior goodwill impairments, tax adjustments and other special items still affect GAAP comparisons and introduce modeling uncertainty — some investors may be trimming positions until recurring earnings visibility is clearer. Full release: reconciliations and note on adjustments
• Negative Sentiment: Valuation and profit‑taking risk: SYK trades at a premium P/E (~46 on reported metrics) and recent insider selling activity may encourage short‑term profit‑taking despite the beat. Analyst comparison & metrics

Stryker Price Performance

Shares of NYSE:SYK opened at $354.39 on Friday. Stryker Corporation has a one year low of $329.16 and a one year high of $404.87. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.85 and a quick ratio of 1.13. The company has a market cap of $135.52 billion, a price-to-earnings ratio of 46.57, a PEG ratio of 2.29 and a beta of 0.89. The firm has a 50 day simple moving average of $359.38 and a 200 day simple moving average of $371.95.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, January 29th. The medical technology company reported $4.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.40 by $0.07. Stryker had a net margin of 12.07% and a return on equity of 24.07%. The company had revenue of $7.17 billion during the quarter, compared to the consensus estimate of $7.12 billion. During the same period in the prior year, the business earned $4.01 earnings per share. The company’s revenue for the quarter was up 11.4% compared to the same quarter last year. Research analysts predict that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Wednesday, December 31st will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 1.0%. This is an increase from Stryker’s previous quarterly dividend of $0.84. The ex-dividend date is Wednesday, December 31st. Stryker’s dividend payout ratio (DPR) is presently 46.25%.

Insider Activity

In related news, CFO Preston Wendell Wells sold 165 shares of the firm’s stock in a transaction that occurred on Thursday, November 20th. The shares were sold at an average price of $365.88, for a total value of $60,370.20. Following the completion of the transaction, the chief financial officer owned 6,694 shares in the company, valued at $2,449,200.72. This trade represents a 2.41% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Ronda E. Stryker sold 276,173 shares of Stryker stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $353.28, for a total transaction of $97,566,397.44. Following the sale, the director owned 2,702,108 shares in the company, valued at approximately $954,600,714.24. This represents a 9.27% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 522,118 shares of company stock valued at $185,381,932 over the last quarter. 5.90% of the stock is owned by company insiders.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.